2018

04/26/2018 Guerbet announces the acquisition of a new microsphere technology to strengthen its interventional imaging range

• Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization; • This new technology will round out Guerbet’s Interventional Imaging solutions and create synergies with the Accurate range of anti-reflux...

[more]


04/18/2018 1st quarter 2018 revenue

1st quarter 2018 revenue €196.5 million at constant exchange rates: -3.2% Villepinte, April 18, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €183.2 million for the 1st quarter 2018, down 9.8% at current...

[more]


04/18/2018 GEAR 2023 strategic plan

Villepinte, April 18, 2018 – Guerbet (the “Company”), a global specialist in contrast agents and solutions for medical imaging, has released today its GEAR 2023 strategic plan. About Guerbet Guerbet is a leading global medical imaging player. The Company engages in the research, production...

[more]


04/13/2018 Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study

Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study aimed at evaluating the activating effects of Lipiodol®-based conventional transarterial chemoembolization (cTACE) on the immunity of patients with hepatocellular carcinoma (HCC)

[more]


04/11/2018 GUERBET to present its solutions offering at the ECIO in Vienna, Austria from 22 to 25 April 2018

∙ A major event, the ECIO brings together international interventional oncology experts every year ∙ Organization of a symposium “New perspectives in cTACE to improve the treatment of HCC patients” on April 23 from 13:45 to 14:30. Villepinte (France), April 11, 2018 (6:00 PM CEST) – Guerbet...

[more]


03/27/2018 2017 Annual Results: Satisfactory activity slightly exceeding the objectives

> EBITDA increased by 22.4% to €130 million> Net income up 60% at €46.2 million > Ongoing debt reduction (leverage ratio of 2.1) Villepinte, March 27, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has announced its...

[more]


02/27/2018 Guerbet teams will attend ECR 2018!

ECR 2018 ӏ Guerbet Booth #220 - Expo X2 ӏ February 28 to March 4 ӏ Vienna, Austria

[more]


Displaying results 1 to 7 out of 11
<< First < Previous 1-7 8-11 Next > Last >>